KRAS - The Cancer Antibody Atlas

← Home Vision Tech About

Gene Information

Gene Name: KRAS

Synonyms: K-Ras4B, KRAS1, KRAS2

Description: KRAS proto-oncogene, GTPase

Protein Class: Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, RAS pathway related proteins

Ensembl ID: ENSG00000133703

UniProt ID: P01116

View in Ensembl View in UniProt View in Human Protein Atlas

RNA Tissue Specific nTPM: Not available

RNA Single Cell Type Specific nTPM: Not available

RNA Tissue Cell Type Enrichment: Not available

RNA Cancer Specificity: Low cancer specificity

RNA Cancer Specific FPKM: Not available

NCBI Summary: This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]

Subcellular Localization

This protein has been detected in 1 cellular location:

Loading cell diagram...

Detected Locations:

Cytosol

Seromics Data

Antibody reactivity data from protein arrays and peptide libraries.

HuProt 635 (IgG)

Human proteome microarrays detect autoantibodies against 21,000 full-length proteins via fluorescent immunoassay (HuProt). Median foreground intensity (MFI) from duplicate spots are averaged and log2-transformed. Hits are called when Z-score ≥3 across the array and signal is >4-fold above secondary-only control MFI for that protein. Displayed are Z-scores for patients passing this threshold; non-hits shown as zero. All data are binarized into hit / no-hit for statistics for case vs cohort and case vs control analysis via Fisher exact test with BH correction. Complete data with antigen sequences available for download below. Learn more about our assay platforms.

Download Statistics Download Z-Score Hits

Comparison:

Group:

Association:

Grayed = mixed directions shown

ID	Name	Total Hits
JHU00236.B4C19R2	KRAS\|P01116-2	13/263
JHU11656.B12C32R6	KRAS\|P01116	0/263
JHU13939.B11C29R38	KRAS\|P01116-2	92/263

Statistical Analysis

ID	Name	Platform	Group	Comparison	P-value	BH Adjusted	Significant	Log OR	Hits Group	Hits Comparison
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_635	Vietnam_Hepatitis_B	vs_control	0.012	0.417	No	1.475	29/60	4/23
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_635	Vietnam_Hepatitis_B	vs_cohort	0.020	0.432	No	0.729	29/60	63/203
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_635	Vietnam_HCC	vs_cohort	0.153	0.775	No	-0.405	36/120	56/143
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_635	Vietnam_Cirrohosis	vs_control	0.115	0.883	No	1.071	23/60	4/23
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_635	Vietnam_HCC	vs_control	0.311	0.893	No	0.706	36/120	4/23
JHU00236.B4C19R2	KRAS\|P01116-2	HuProt_635	Vietnam_Hepatitis_B	vs_cohort	0.501	1.000	No	0.430	4/60	9/203
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_635	Vietnam_Cirrohosis	vs_cohort	0.541	1.000	No	0.188	23/60	69/203
JHU00236.B4C19R2	KRAS\|P01116-2	HuProt_635	Vietnam_HCC	vs_cohort	0.777	1.000	No	-0.309	5/120	8/143
JHU00236.B4C19R2	KRAS\|P01116-2	HuProt_635	Vietnam_Cirrohosis	vs_cohort	1.000	1.000	No	0.016	3/60	10/203
JHU00236.B4C19R2	KRAS\|P01116-2	HuProt_635	Vietnam_Cirrohosis	vs_control	1.000	1.000	No	0.145	3/60	1/23
JHU00236.B4C19R2	KRAS\|P01116-2	HuProt_635	Vietnam_HCC	vs_control	1.000	1.000	No	-0.044	5/120	1/23
JHU00236.B4C19R2	KRAS\|P01116-2	HuProt_635	Vietnam_Hepatitis_B	vs_control	1.000	1.000	No	0.447	4/60	1/23

HuProt 532 (IgA)

The same HuProt microarray assay as-described above; additionally stained with an anti-IgA secondary. Learn more about our assay platforms.

Download Statistics Download Z-Score Hits

Comparison:

Group:

Association:

Grayed = mixed directions shown

ID	Name	Total Hits
JHU00236.B4C19R2	KRAS\|P01116-2	1/263
JHU11656.B12C32R6	KRAS\|P01116	0/263
JHU13939.B11C29R38	KRAS\|P01116-2	11/263

Statistical Analysis

ID	Name	Platform	Group	Comparison	P-value	BH Adjusted	Significant	Log OR	Hits Group	Hits Comparison
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_532	Vietnam_HCC	vs_cohort	0.071	0.575	No	-1.372	2/120	9/143
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_532	Vietnam_HCC	vs_control	0.411	0.938	No	-0.977	2/120	1/23
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_532	Vietnam_Cirrohosis	vs_cohort	0.279	1.000	No	0.690	4/60	7/203
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_532	Vietnam_Hepatitis_B	vs_cohort	0.279	1.000	No	0.690	4/60	7/203
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_532	Vietnam_Cirrohosis	vs_control	1.000	1.000	No	0.447	4/60	1/23
JHU13939.B11C29R38	KRAS\|P01116-2	HuProt_532	Vietnam_Hepatitis_B	vs_control	1.000	1.000	No	0.447	4/60	1/23

HuScan Peptide Library

Human phage display immunoprecipitation-sequencing (PhIP-Seq) detects autoantibodies via a >700,000 49mer peptide library covering the human proteome (HuScan). Raw phage counts enriched in each sample are compared to mock-immunoprecipitation controls (beadsonly) via edgeR. Hits are called when P ≤0.0001 and >4-fold above edgeR-computed background. Displayed are log2 fold-changes for patients passing this threshold for peptides matching this gene; non-hits shown as zero. All data are binarized into hit / no-hit for statistics for case vs cohort and case vs control analysis via Fisher exact test with BH correction. Complete data with peptide sequences available for download below. Learn more about our assay platforms.

A total of 7 peptides included in assay; 0 above visualization threshold.

Download Statistics Download edgeR Hits

ID	Name	Total Hits	Control_Pooled (n=23)																							Vietnam_HCC (n=120)																																																																Vietnam_Cirrohosis (n=60)																																																												Vietnam_Hepatitis_B (n=60)
No targets above threshold for visualization

Statistical Analysis

No targets above threshold for statistical analysis

TCGA Hotspot Neoantigens & Mutation Data

Mutation hotspot data from The Cancer Genome Atlas (TCGA). Created via analyzing 10,437 unique patient tumors across 33 cancer types (Thorsson et al., 2018).

Mutation frequency analysis from The Cancer Genome Atlas (TCGA) showing hotspot neoantigens for KRAS.

Detailed Hotspot Mutations

Mutation hotspots identified from TCGA data corresponding to the visualization above.

Gene	Transcript	Variant	Frequency	Cancer Types	Window Start	Window End	Peptide Sequences
KRAS	`ENST00000256078`	Missense_Mutation G12D	1.77%	GBM;PAAD;LUAD;COAD;KIRP;UCEC;LAML;READ;STAD;CESC;BLCA;LIHC;BRCA;SKCM;ESCA;UCS;PRAD;THYM	1	28	GGGSGMTEYKLVVVGAGGVGKSALTIQLIQNHF GGGSGMTEYKLVVVGADGVGKSALTIQLIQNHF
KRAS	`ENST00000256078`	Missense_Mutation G12V	1.51%	LUAD;OV;TGCT;PAAD;KIRP;LUSC;COAD;UCEC;LAML;READ;BRCA;BLCA;CESC;THCA;STAD;UCS	1	28	GGGSGMTEYKLVVVGAGGVGKSALTIQLIQNHF GGGSGMTEYKLVVVGAVGVGKSALTIQLIQNHF
KRAS	`ENST00000256078`	Missense_Mutation G12C	0.92%	LUAD;LIHC;COAD;READ;UCEC;BRCA;KIRC;STAD;BLCA;SKCM;CESC;PAAD;UCS;MESO	1	28	GGGSGMTEYKLVVVGAGGVGKSALTIQLIQNHF GGGSGMTEYKLVVVGACGVGKSALTIQLIQNHF
KRAS	`ENST00000256078`	Missense_Mutation G13D	0.66%	LUAD;BLCA;COAD;UCEC;LAML;READ;STAD;CESC;LIHC;SKCM	1	29	GGGSMTEYKLVVVGAGGVGKSALTIQLIQNHFV GGGSMTEYKLVVVGAGDVGKSALTIQLIQNHFV
KRAS	`ENST00000256078`	Missense_Mutation G12A	0.36%	TGCT;LUAD;LUSC;COAD;READ;UCEC;PAAD;UCS;LGG	1	28	GGGSGMTEYKLVVVGAGGVGKSALTIQLIQNHF GGGSGMTEYKLVVVGAAGVGKSALTIQLIQNHF
KRAS	`ENST00000256078`	Missense_Mutation G12R	0.31%	OV;PAAD;CHOL;SKCM;COAD;BLCA;TGCT;PRAD	1	28	GGGSGMTEYKLVVVGAGGVGKSALTIQLIQNHF GGGSGMTEYKLVVVGARGVGKSALTIQLIQNHF
KRAS	`ENST00000256078`	Missense_Mutation G12S	0.22%	PAAD;LUAD;TGCT;COAD;READ;UCEC;STAD	1	28	GGGSGMTEYKLVVVGAGGVGKSALTIQLIQNHF GGGSGMTEYKLVVVGASGVGKSALTIQLIQNHF
KRAS	`ENST00000256078`	Missense_Mutation A146T	0.20%	UCEC;COAD;READ;STAD;CESC	130	162	AQDLARSYGIPFIETSAKTRQRVEDAFYTLVRE AQDLARSYGIPFIETSTKTRQRVEDAFYTLVRE
KRAS	`ENST00000256078`	Missense_Mutation Q61H	0.19%	TGCT;LUSC;LUAD;UCEC;COAD;READ;STAD;PAAD;BLCA;SARC	45	77	VIDGETCLLDILDTAGQEEYSAMRDQYMRTGEG VIDGETCLLDILDTAGHEEYSAMRDQYMRTGEG
KRAS	`ENST00000256078`	Missense_Mutation G13C	0.13%	LUAD;COAD;UCEC;SARC;PAAD;LUSC	1	29	GGGSMTEYKLVVVGAGGVGKSALTIQLIQNHFV GGGSMTEYKLVVVGAGCVGKSALTIQLIQNHFV
KRAS	`ENST00000256078`	Missense_Mutation Q61L	0.08%	TGCT;OV;LUAD;READ;UCEC;SKCM	45	77	VIDGETCLLDILDTAGQEEYSAMRDQYMRTGEG VIDGETCLLDILDTAGLEEYSAMRDQYMRTGEG
KRAS	`ENST00000256078`	Missense_Mutation Q61K	0.07%	COAD;SKCM;THCA;CHOL	45	77	VIDGETCLLDILDTAGQEEYSAMRDQYMRTGEG VIDGETCLLDILDTAGKEEYSAMRDQYMRTGEG
KRAS	`ENST00000256078`	Missense_Mutation L19F	0.06%	LUAD;COAD;BLCA;DLBC	3	35	EYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPT EYKLVVVGAGGVGKSAFTIQLIQNHFVDEYDPT
KRAS	`ENST00000256078`	Missense_Mutation Q61R	0.06%	PAAD;COAD;THCA;SKCM;TGCT	45	77	VIDGETCLLDILDTAGQEEYSAMRDQYMRTGEG VIDGETCLLDILDTAGREEYSAMRDQYMRTGEG
KRAS	`ENST00000256078`	Missense_Mutation K117N	0.05%	COAD;READ;SKCM	101	133	KRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDL KRVKDSEDVPMVLVGNNCDLPSRTVDTKQAQDL
KRAS	`ENST00000256078`	Missense_Mutation A59T	0.04%	READ;STAD	43	75	QVVIDGETCLLDILDTAGQEEYSAMRDQYMRTG QVVIDGETCLLDILDTTGQEEYSAMRDQYMRTG
KRAS	`ENST00000256078`	Missense_Mutation A59G	0.03%	UCEC;KIRC;BLCA	43	75	QVVIDGETCLLDILDTAGQEEYSAMRDQYMRTG QVVIDGETCLLDILDTGGQEEYSAMRDQYMRTG
KRAS	`ENST00000256078`	Missense_Mutation A146V	0.03%	UCEC;COAD;TGCT	130	162	AQDLARSYGIPFIETSAKTRQRVEDAFYTLVRE AQDLARSYGIPFIETSVKTRQRVEDAFYTLVRE

Show all 18 mutation sites Show first 5 mutation sites ▼

● Normal amino acid at mutation position

● Mutated amino acid at mutation position

TCGA Cancer Prognostics

Prognostic data from The Cancer Genome Atlas (TCGA). Summaries created by the Human Protein Atlas via analyzing gene expression impact on patient survival across multiple cancer types.

Breast Invasive Carcinoma

7.54e-3

Breast Invasive Carcinoma (val)

2.14e-1

Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma

4.34e-4

Colon Adenocarcinoma

9.27e-2

Colon Adenocarcinoma (val)

1.13e-1

Glioblastoma Multiforme

1.23e-1

Glioblastoma Multiforme (val)

1.97e-1

Head and Neck Squamous Cell Carcinoma

3.55e-1

Kidney Chromophobe

9.60e-2

Kidney Renal Clear Cell Carcinoma

1.57e-6

Kidney Renal Clear Cell Carcinoma (val)

2.69e-2

Kidney Renal Papillary Cell Carcinoma

7.19e-3

Liver Hepatocellular Carcinoma

2.56e-2

Liver Hepatocellular Carcinoma (val)

2.37e-1

Lung Adenocarcinoma

3.46e-4

Lung Adenocarcinoma (val)

8.79e-2

Lung Squamous Cell Carcinoma

4.19e-2

Lung Squamous Cell Carcinoma (val)

5.92e-2

Ovary Serous Cystadenocarcinoma

1.21e-1

Ovary Serous Cystadenocarcinoma (val)

7.44e-2

Pancreatic Adenocarcinoma

2.38e-3

Pancreatic Adenocarcinoma (val)

5.24e-3

Prostate Adenocarcinoma

6.67e-2

Rectum Adenocarcinoma

1.25e-1

Rectum Adenocarcinoma (val)

3.71e-2

Skin Cuteneous Melanoma

1.74e-1

Stomach Adenocarcinoma

2.26e-1

Testicular Germ Cell Tumor

2.20e-1

Thyroid Carcinoma

1.47e-2

Uterine Corpus Endometrial Carcinoma

3.46e-1

Not Available

Unprognostic

Validated Unfavorable

Potential Unfavorable

Potential Favorable

Validated Favorable